REFERENCES

• WhitefordHA.DegenhardtL.RehmJ.et alGlobal burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.Lancet.20133821575158623993280
   PubMed Web of Science ®Google Scholar
• MrazekDA.HornbergerJC.AltarCA.DegtiarI.A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013.Psychiatr Serv.20146597798724789696
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders.J Clin Pyschiatry199758suppl 132329
   Google Scholar
• NierenbergAA.DeCeccoLM.Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression.J Clin Pyschiatry.200162suppl 1659
   PubMedGoogle Scholar
• RushAJ.TrivediMH.WisniewskiSR.et alAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.Am J Psychiatry.20061631905191717074942
   PubMed Web of Science ®Google Scholar
• ThaseME.Evaluating antidepressant therapies: remission as the optimal outcome.J Clin Pyschiatry.200364suppl 131825
   PubMedGoogle Scholar
• BoulengerJP.Residual symptoms of depression: clinical and theoretical implications.Eur Psychiatry.20041920921315196602
   PubMed Web of Science ®Google Scholar
• PaykelES.RamanaR.CooperZ.HayhurstH.KerrJ.BarockaA.Residual symptoms after partial remission: an important outcome in depression.Psychol Med.199525117111808637947
   PubMed Web of Science ®Google Scholar
• GaynesBN.WardenD.TrivediMH.WisniewskiSR.FavaM.RushAJ.What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.Psychiatr Sen.20096014391445
   PubMed Web of Science ®Google Scholar
• TrivediMH.RushAJ.WisniewskiSR.et alEvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.Am J Psychiatry.2006163284016390886
   PubMed Web of Science ®Google Scholar
• TrevinoK.McClintockSM.McDonald FischerN.VoraA.HusainMM.Defining treatment-resistant depression: A comprehensive review of the literature.Ann Clin Psychiatry.20142622223225166485
   PubMed Web of Science ®Google Scholar
• RuheHG.van RooijenG.SpijkerJ.PeetersFP.ScheneAH.Staging methods for treatment resistant depression. A systematic review.J Affect Disord.2012137354521435727
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual Of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing2013
   Google Scholar
• RushAJ.WardenD.WisniewskiSR.et alSTAR*D: revising conventional wisdom.CNS Drugs.20092362764719594193
   PubMed Web of Science ®Google Scholar
• FavaM.AlpertJE.CarminCN.et alClinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D.Psychol Med.2004341299130815697056
   PubMed Web of Science ®Google Scholar
• FavaM.RankinMA.WrightEC.et alAnxiety disorders in major depression.Compr Psychiatry.2000419710210741886
   PubMed Web of Science ®Google Scholar
• SandersonWC.BeckAT.BeckJ.Syndrome comorbidity in patients with major depression or dysthymia: prevalence and temporal relationships.Am J Psychiatry.1990147102510282375436
   PubMed Web of Science ®Google Scholar
• IonescuDF.NiciuMJ.MathewsDC.RichardsEM.ZarateCA.Jr.Neurobiology of anxious depression: a review.Depress Anxiety.201330437438523495126
   PubMed Web of Science ®Google Scholar
• IonescuDF.NiciuM.RichardsEM.ZarateCA.Pharmacologic treatment of dimensional anxious depression: a review.Prim Care Companion CNS Disord.201416 [Epub ahead of print]3
   Google Scholar
• TakahashiM.ShirayamaY.MuneokaK.SuzukiM.SatoK.HashimotoK.Personality traits as risk factors for treatment-resistant depression.PloS One.20138e6375623717477
   PubMed Web of Science ®Google Scholar
• KellyK.PosternakM.AlpertJE.Toward achieving optimal response: understanding and managing antidepressant side effects.Dialogues Clin Neurosci.20081040941819170398
   PubMedGoogle Scholar
• KuoHW.LiuSC.TsouHH.et alCYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions.Pharmacogenomics.2013141191120123859573
   PubMed Web of Science ®Google Scholar
• ZhouSF.YangLP.ZhouSF.LiuYH.ChanE.Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1 A2.AA.PSJ.200911481494
   Google Scholar
• WashioI.MaedaM.SugiuraC.et alCigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes.Drug MetabDispos.201139113
   PubMed Web of Science ®Google Scholar
• HaslemoT.EikesethPH.TanumL.MoldenE.RefsumH.The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.Eur J Clin Pharmacol.2006621049105317089108
   PubMed Web of Science ®Google Scholar
• HowellT.Managing medical and psychiatric comorbidities.WMJ.20041036232715622813
   PubMedGoogle Scholar
• AlpertJ.Drug-Drug Interactions in Psychopharmacology.New York, NY: McGraw-Hill; 2012
   Google Scholar
• WeilburgJB.O'LearyKM.MeigsJB.HennenJ.StaffordRS.Evaluation of the adequacy of outpatient antidepressant treatment.Psychiatric Serv.20035412331239
   PubMed Web of Science ®Google Scholar
• TrivediRB.NieuwsmaJA.WilliamsJW.Jr.Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review.J Gen Int Med.201126643650
   PubMed Web of Science ®Google Scholar
• CusinC.DoughertyDD.Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS.Biol Mood Anxiety Disord.201221422901565
   PubMedGoogle Scholar
• QureshiNA.Al-BedahAM.Mood disorders and complementary and alternative medicine: a literature review.Neuropsychiatr Dis Treat.2013963965823700366
   PubMed Web of Science ®Google Scholar
• FavaM.Diagnosis and definition of treatment-resistant depression.Biol Psychiatry.20035364965912706951
   PubMed Web of Science ®Google Scholar
• RushAJ.STAR*D: what have we leamed 4m7Psyc/i/3&y. 2007164201204
   Google Scholar
• McIntyreRS.FilteauMJ.MartinL.et alTreatment-resistant depression: definitions, review of the evidence, and algorithmic approach.J Affect Disord.20141561724314926
   PubMed Web of Science ®Google Scholar
• MahmoudRA.PandinaGJ.TurkozI.et alRisperidone for treatment-refractory major depressive disorder: a randomized trial.Ann int Med200714759360217975181
   PubMed Web of Science ®Google Scholar
• PapakostasGl.PetersenTJ.NierenbergAA.et alZiprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.J Clin Pyschiatry.200465217221
   PubMed Web of Science ®Google Scholar
• SpielmansGl.BermanMl.LinardatosE.RosenlichtNZ.PerryA.TsaiAC.Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes.PLoS Med.201310e100140323554581
   PubMed Web of Science ®Google Scholar
• NelsonJC.PapakostasGl.Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.Am J Psychiatry.200916698099119687129
   PubMed Web of Science ®Google Scholar
• PapakostasGl.SheltonRC.SmithJ.FavaM.Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis.J Clin Pyschiatry.200768826831
   PubMed Web of Science ®Google Scholar
• ChaDS.MclntyreRS.Treatment-emergent adverse events associated with atypical antipsychotics.Exp Opin Pharmacother.20121315871598
   PubMed Web of Science ®Google Scholar
• BauerM.AdliM.RickenR.SeverusE.PilhatschM.Role of lithium augmentation in the management of major depressive disorder.CNS Drugs.20142833134224590663
   PubMed Web of Science ®Google Scholar
• IosifescuDV.BoloNR.NierenbergAA.JensenJE.FavaM.RenshawPF.Brain bioenergeticsand response to triiodothyronine augmentation in major depressive disorder.Biol Psychiatry.2008631127113418206856
   PubMed Web of Science ®Google Scholar
• LifschytzT.SegmanR.ShalomG.et alBasic mechanisms of augmentation of antidepressant effects with thyroid hormone.Curr Drug Targets.2006720321016475961
   PubMed Web of Science ®Google Scholar
• CarvalhoAF.BerkM.HyphantisTN.MclntyreRS.The integrative management of treatment-resistant depression: a comprehensive review and perspectives.Psychother Psychosomat.2014837088
   PubMed Web of Science ®Google Scholar
• AronsonR.OffmanHJ.JoffeRT.NaylorCD.Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis.Arch Gen Psychiatry.1996538428488792761
   PubMed Web of Science ®Google Scholar
• NierenbergAA.FavaM.TrivediMH.et alA comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.Am J Psychiatry.2006163151930; quiz 66516946176
   PubMed Web of Science ®Google Scholar
• SmithRS.The macrophage theory of depression.Med Hypotheses.1991352983061943879
   PubMed Web of Science ®Google Scholar
• LotrichFE.Inflammatory cytokine-associated depression.Brain Res.2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• NaKS.LeeKJ.LeeJS.ChoYS.JungHY.Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis.Prog Neuropsychopharmacol Biol Psychiatry.201448798524056287
   PubMed Web of Science ®Google Scholar
• RaisonCL.RutherfordRE.WoolwineBJ.et alA randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.JAMA Psychiatry.201370314122945416
   PubMed Web of Science ®Google Scholar
• BlochMH.HannestadJ.Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis.Mol Psychiatry.2012171272128221931319
   PubMed Web of Science ®Google Scholar
• BedsonE.BellD.CarrD.et alFolate Augmentation of Treatment-Evaluation for Depression (FolATED): randomised trial and economic evaluation.Health TechnoI Assess.20141848viiviii, 1-159
   PubMed Web of Science ®Google Scholar
• RobertsSH.BedsonE.HughesD.et alFolate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial.BMCP Psychiatry.2007765
   PubMed Web of Science ®Google Scholar
• PapakostasGl.CassielloCF.lovienoN.Folates and S-adenosylmethionine for major depressive disorder.Can J Psychiatry.20125740641322762295
   PubMed Web of Science ®Google Scholar
• PapakostasGl.SheltonRC.ZajeckaJM.et alL-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.Am J Psychiatry.20121691267127423212058
   PubMed Web of Science ®Google Scholar
• PapakostasGl.SheltonRC.ZajeckaJM.et alEffect of adjunctive Lmethylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial.J Clin Pyschiatry.201475855863
   PubMed Web of Science ®Google Scholar
• AlpertJE.PapakostasG.MischoulonD.et alS-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine.J Clin Psychopharmacol.20042466166415538131
   PubMed Web of Science ®Google Scholar
• PapakostasGl.MischoulonD.ShyuI.AlpertJE.FavaM.S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a doubleblind, randomized clinical trial.Am J Psychiatry.201016794294820595412
   PubMed Web of Science ®Google Scholar
• MischoulonD.PriceLH.CarpenterLL.et alA double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.J Clin Pyschiatry.201475370376
   PubMed Web of Science ®Google Scholar
• IonescuDF.NiciuMJ.HenterID.ZarateCA.Defining anxious depression: a review of the literature.CNS Spectr.201319
   PubMed Web of Science ®Google Scholar
• DunlopBW.DavisPG.Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review.Prim Care Companion J Clin Pyschiatry.200810222228
   PubMedGoogle Scholar
• NolenWA.HaffmansPM.BouvyPF.DuivenvoordenHJ.Hypnotics as concurrent medication in depression. A placebo-controlled, doubleblind comparison of flunitrazepam and lormetazepam in patients with major depression, treated with a (tri)cyclic antidepressant.J Affect Disord.1993281791888104964
   PubMed Web of Science ®Google Scholar
• SmithWT.LondborgPD.GlaudinV.PainterJR.Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study.Am J Psychiatry.19981551339459766764
   PubMed Web of Science ®Google Scholar
• FavaM.McCallWV.KrystalA.et alEszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.Biol Psychiatry.2006591052106016581036
   PubMed Web of Science ®Google Scholar
• ZajeckaJM.Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances.J Clin Pyschiatry201374suppl 2913
   PubMedGoogle Scholar
• GossAJ.KaserM.CostafredaSG.SahakianBJ.FuCH.Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.J Clin Pyschiatry.20137411011107
   PubMed Web of Science ®Google Scholar
• GeddesJR.CalabreseJR.GoodwinGM.Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials.Br J Psychiatry.20091944919118318
   PubMed Web of Science ®Google Scholar
• ThomasSP.NandhraHS.JayaramanA.Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD).J Ment Health.20101916817520433324
   PubMed Web of Science ®Google Scholar
• LandenM.BjorlingG.AgrenH.FahlenT.A randomized, doubleblind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.J Clin Pyschiatry.199859664668
   PubMed Web of Science ®Google Scholar
• AppelbergBG.SyvalahtiEK.KoskinenTE.MehtonenOP.MuhonenTT.NaukkarinenHH.Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.J Clin Pyschiatry200162448452
   PubMed Web of Science ®Google Scholar
• TrivediMH.FavaM.WisniewskiSR.et alMedication augmentation after the failure of SSRIs for depression.N Engl J Med.200635412435216554526
   PubMed Web of Science ®Google Scholar
• BallesterosJ.CalladoLF.Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials.J Affect Disord.20047913714715023488
   PubMed Web of Science ®Google Scholar
• WhaleR.TeraoT.CowenP.FreemantleN.GeddesJ.Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review.J Psychopharmacol.20102451352018832428
   PubMed Web of Science ®Google Scholar
• MartinyK.LundeM.BechP.PlengeP.A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression.Nordic J Psychiatry.201266147154
   PubMed Web of Science ®Google Scholar
• PierceyMF.Pharmacology of pramipexole, a dopamine OS-preferring agonist useful in treating Parkinson's disease.Clin Neuropharrnacol.19982114151
   PubMed Web of Science ®Google Scholar
• CusinC.lovienoN.IosifescuDV.et alA randomized, doubleblind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.J Clin Pyschiatry.201374e636e641
   PubMed Web of Science ®Google Scholar
• Franco-ChavesJA.MateusCF.LuckenbaughDA.MartinezPE.MallingerAG.ZarateCAJr.Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a doubleblind, randomized pilot study.J Affect Disord.20131493192523517885
   PubMed Web of Science ®Google Scholar
• PatkarAA.MasandPS.PaeCU.et alA randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.J Clin Psychopharmacol.20062665365617110825
   PubMed Web of Science ®Google Scholar
• RavindranAV.KennedySH.O'DonovanMC.FalluA.CamachoF.BinderCE.Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.J Clin Pyschiatry.2008698794
   PubMed Web of Science ®Google Scholar
• AmanatkarHR.ChibnallJT.SeoBW.ManepalliJN.GrossbergGT.Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials.Ann Clin Psychiatry.201426193224501728
   PubMed Web of Science ®Google Scholar
• HowlandRH.Use of endocrine hormones for treating depression.J Psychosoc Nurs Ment Health Serv.2010481316
   Web of Science ®Google Scholar
• KlinedinstNJ.RegenoldWT.A mitochondrial bioenergetic basis of depression.J Bioenerget Biomembr.2015471-2155171
   PubMed Web of Science ®Google Scholar
• NierenbergAA.KanskyC.BrennanBP.SheltonRC.PerlisR.IosifescuDV.Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development.Aust N Z J Psychiatry.201347264222711881
   PubMed Web of Science ®Google Scholar
• FavaM.TargurnSD.NierenbergAA.et alAn exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery.J Psychiatr Res.2012461553156322998742
   PubMed Web of Science ®Google Scholar
• WangSM.HanC.LeeSJ.PatkarAA.MasandPS.PaeCU.A review of current evidence for acetyl-l-carnitine in the treatment of depression.J Psychiatr Res.201453303724607292
   PubMed Web of Science ®Google Scholar
• GarzyaG.CoralloD.FioreA.LeccisoG.PetrelliG.ZottiC.Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression.Drugs. under experimental and clinical research.1990161011062205455
   PubMedGoogle Scholar
• PettegrewJW.LevineJ.GershonS.et al31P-MRS study of acetylL-carnitine treatment in geriatric depression: preliminary results.Bipolar Disord.20024616612047496
   PubMed Web of Science ®Google Scholar
• BrennanBP.JensenJE.HudsonJl.et alA placebo-controlled trial of acetyl-L-carnitine and alpha-lipoic acid in the treatment of bipolar depression.J Clin Psychopharmacol.20133362763523948785
   PubMed Web of Science ®Google Scholar
• LyooIK.YoonS.KimTS.et alA randomized, double-blind placebocontrolled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.Am J Psychiatry.201216993794522864465
   PubMed Web of Science ®Google Scholar
• NemetsB.LevineJ.A pilot dose-finding clinical trial of creatine monohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major depression.Int Clin Psychopharmacol.20132812713323466591
   PubMed Web of Science ®Google Scholar
• GaynesBN.DusetzinaSB.EllisAR.et alTreating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.J Clin Psychopharmacol.20123211411922198447
   PubMed Web of Science ®Google Scholar
• RuheHG.HuyserJ.SwinkelsJA.ScheneAH.Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.J Clin Pyschiatry.20066718361855
   PubMed Web of Science ®Google Scholar
• PapakostasGl.FavaM.ThaseME.Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches.Biol Psychiatry.20086369970417919460
   PubMed Web of Science ®Google Scholar
• RushAJ.TrivediMH.WisniewskiSR.et alBupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.N Engl J Med.20063541231124216554525
   PubMed Web of Science ®Google Scholar
• FangY.YuanC.XuY.et alComparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.J Clin Psychopharmacol.20103035736420571433
   PubMed Web of Science ®Google Scholar
• ConnollyKR.ThaseME.If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.Drugs.201171436421175239
   PubMed Web of Science ®Google Scholar
• FavaM.RushAJ.WisniewskiSR.et alA comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.Am J Psychiatry.20061631161117216816220
   PubMed Web of Science ®Google Scholar
• PereiraVM.Arias-CarrionO.MachadoS.NardiAE.SilvaAC.Bupropion in the depression-related sexual dysfunction: a systematic review.CNS Neurol Disord Drug Targets.2014131079108824923342
   PubMed Web of Science ®Google Scholar
• MontgomerySA.NielsenRZ.PoulsenLH.HaggstromL.A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.Hum Psychopharmacol.201429547048225087600
   PubMed Web of Science ®Google Scholar
• ThaseME.RushAJ.HowlandRH.et alDouble-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.Arch Gen Psychiatry.20025923323911879161
   PubMed Web of Science ®Google Scholar
• ThaseME.The role of monoamine oxidase inhibitors in depression treatment guidelines.J Clin Pyschiatry.201273suppl 11016
   PubMedGoogle Scholar
• McGrathPJ.StewartJW.NunesEV.et alA double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression.Am J Psychiatry.19931501181238417553
   PubMed Web of Science ®Google Scholar
• McGrathPJ.StewartJW.FavaM.et alTranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.Am J Psychiatry.200616315311541; quiz 66616946177
   PubMed Web of Science ®Google Scholar
• RochaFL.FuzikawaC.RieraR.HaraC.Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis.J Clin Psychopharmacol.20123227828122367652
   PubMed Web of Science ®Google Scholar
• StewartJW.McGrathPJ.BlondeauC.et alCombination antidepressant therapy for major depressive disorder: speed and probability of remission.J Psychiatr Res.20145271424485847
   PubMed Web of Science ®Google Scholar
• RushAJ.TrivediMH.StewartJW.et alCombining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.Am J Psychiatry.201116868970121536692
   PubMed Web of Science ®Google Scholar
• Lopes RochaF.FuzikawaC.RieraR.RamosMG.HaraC.Antidepressant combination for major depression in incomplete responders-a systematicreview. J Affect Disord.20131441622835845
   PubMed Web of Science ®Google Scholar
• Stedman's Medical Dictionary. Philadelphia, PA: Lippincott, Williams, and Wilkins.2000
   Google Scholar
• KatzG.Tachyphylaxis/tolerance to antidepressive medications: a review.Isr J Psychiatry Relat Sci.20114812913522120449
   PubMed Web of Science ®Google Scholar
• BermanRM.CappielloA.AnandA.et alAntidepressant effects of ketamine in depressed patients.Biol Psychiatry20004735135410686270
   PubMed Web of Science ®Google Scholar
• SosP.KlirovaM.NovakT.KohutovaB.HoracekJ.PalenicekT.Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.Neuroendocrinol Lett.20133428729323803871
   PubMed Web of Science ®Google Scholar
• ZarateCA.Jr.SinghJB.CarlsonPJ.et alA randomized trial of an Nmethyl-D-aspartate antagonist in treatment-resistant major depression.Arch Gen Psychiatry.20066385686416894061
   PubMed Web of Science ®Google Scholar
• MurroughJW.IosifescuDV.ChangLC.et alAntidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.Am J Psychiatry.20131701134114223982301
   PubMed Web of Science ®Google Scholar
• IonescuDF.LuckenbaughDA.NiciuMJ.et alEffect of baseline anxious depression on initial and sustained antidepressant response to ketamine.J Clin Pyschiatry.201475e932e938
   PubMed Web of Science ®Google Scholar
• PhelpsLE.BrutscheN.MoralJR.LuckenbaughDA.ManjiHK.ZarateCA.Jr.Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.Biol Psychiatry.20096518118418996507
   PubMed Web of Science ®Google Scholar
• DiazGranadosN.IbrahimLA.BrutscheNE.et alRapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.J Clin Pyschiatry.20107116051611
   PubMed Web of Science ®Google Scholar
• PriceRB.NockMK.CharneyDS.MathewSJ.Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatmentresistant depression.Biol Psychiatry.20096652252619545857
   PubMed Web of Science ®Google Scholar
• LallyN.NugentAC.LuckenbaughDA.AmeliR.RoiserJP.ZarateCA.Anti-anhedonic effect of ketamine and its neural correlates in treatmentresistant bipolar depression.Transl Psychiatry20144e46925313512
   PubMed Web of Science ®Google Scholar
• BallardED.IonescuDF.Vande VoortJL.et alIncreased fear-potentiated startle in major depressive disorder patients with lifetime history of suicide attempt.J Affect Disord.2014162343348
   Web of Science ®Google Scholar
• LapidusKA.LevitchCF.PerezAM.et alA randomized controlled trial of intranasal ketamine in major depressive disorder.Biol Psychiatry.2014761297097624821196
   PubMed Web of Science ®Google Scholar
• aan het RotM.CollinsKA.MurroughJW.et alSafety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.Biol Psychiatry.20106713914519897179
   PubMed Web of Science ®Google Scholar
• MurroughJW.PerezAM.PillemerS.et alRapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.Biol Psychiatry.20137425025622840761
   PubMed Web of Science ®Google Scholar
• IbrahimL.DiazgranadosN.Franco-ChavesJ.et alCourse of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebocontrolled study.Neuropsychopharmacology2012371526153322298121
   PubMed Web of Science ®Google Scholar
• WanLB.LevitchCF.PerezAM.et alKetamine safety and tolerability in clinical trials for treatment-resistant depression.J Clin Pyschiatry.2014 [Epub ahead of print]
   PubMedGoogle Scholar
• LuckenbaughDA.NiciuMJ.IonescuDF.et alDo the dissociative side effects of ketamine mediate its antidepressant effects?J Affect Disord.2014159566124679390
   PubMed Web of Science ®Google Scholar
• ZunszainPA.HorowitzMA.CattaneoA.LupiMM.ParianteCM.Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties.Mol Psychiatry.2013181236124123877835
   PubMed Web of Science ®Google Scholar
• DumanRS.Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections.Dialogues Clin Neurosci.201416112724733968
   PubMed Web of Science ®Google Scholar
• MathewsDC.ZarateCA.Jr.Current status of ketamine and related compounds for depression.J Clin Pyschiatry.201374516517
   PubMed Web of Science ®Google Scholar
• McGirrA.BerlimMT.BondDJ.FleckMP.YathamLN.LamRW.A systematic review and meta-analysis of randomized, double-blind, placebocontrolled trials of ketamine in the rapid treatment of major depressive episodes.Psychol Med.201445469370425010396
   PubMed Web of Science ®Google Scholar
• FureyML.DrevetsWC.Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.Arch Gen Psychiatry.2006631121112917015814
   PubMed Web of Science ®Google Scholar
• FureyML.DrevetsWC.HoffmanEM.FrankelE.SpeerAM.ZarateCA.Jr.Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder.JAMA Psychiatry.20137028029023364679
   PubMed Web of Science ®Google Scholar
• ZimmermanM.PosternakM.FriedmanM.et alWhich factors influence psychiatrists' selection of antidepressants?Am J Psychiatry.20041611285128915229063
   PubMed Web of Science ®Google Scholar